Patents by Inventor Manuel A. Navia

Manuel A. Navia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating neurological disorders
    Patent number: 11752200
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: September 12, 2023
    Assignee: EnClear Therapies Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE
    Publication number: 20230257357
    Abstract: Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.
    Type: Application
    Filed: June 24, 2021
    Publication date: August 17, 2023
    Applicant: Bacainn Biotherapeutics, Ltd.
    Inventors: Chris Murphy, Ronald Farquhar, Roland E. Dolle, Manuel Navia
  • METHODS OF TREATING NEUROLOGICAL DISORDERS
    Publication number: 20230056486
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 23, 2023
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20220281813
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 8, 2022
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Methods of treating neurological disorders
    Patent number: 11419921
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: August 23, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Methods of amelioration of cerebrospinal fluid and devices and systems therefor
    Patent number: 11278657
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 22, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Anthony DePasqua, Kevin Eggan, Jr., Kevin Kalish, Manuel A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman
  • Therapeutic compounds and compositions
    Patent number: 11198673
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: December 14, 2021
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • METHODS OF TREATING NEUROLOGICAL DISORDERS
    Publication number: 20210154276
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 27, 2021
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • METHODS OF TREATING NEUROLOGICAL DISORDERS
    Publication number: 20210145944
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 20, 2021
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Methods of Amelioration of Cerebrospinal Fluid and Devices and Systems Therefor
    Publication number: 20210023293
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 28, 2021
    Inventors: Anthony DePasqua, Kevin Eggan, JR., Kevin Kalish, Manuel A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190359567
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 27, 2019
    Publication date: November 28, 2019
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 10259785
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: April 16, 2019
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20180244614
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 30, 2018
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9994521
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 12, 2018
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20170037003
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9499532
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 22, 2016
    Assignee: eXIthera Pharmaceuticals Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20150225389
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 13, 2015
    Applicant: EXITHERA PHARMACEUTICALS INC.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • FLAVIN DERIVATIVES
    Publication number: 20130029980
    Abstract: The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives.
    Type: Application
    Filed: April 6, 2011
    Publication date: January 31, 2013
    Inventors: Philip D. G. Coish, Brian R. Dixon, David Osterman, Paul Adrian Aristoff, Manuel Navia, Frank Sciavolino, Stephanie Avola, Nick Baboulas, Thomas R. Belliotti, Angelica Bello, Judd Berman, Robert A. Chrusciel, Bruce R. Evans, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Phil Wickens, Jeffrey Wilson, Heinrich J. Schostarez
  • FLAVIN DERIVATIVES
    Publication number: 20120295903
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 22, 2012
    Inventors: Kenneth F. Blount, Philip D.G. Coish, Brian R. Dixon, Jayhyuk Myung, David Osterman, Phil Wickens, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Jeffrey Wilson, Jeffrey A. Leiby, Dennis Underwood, Paul Adrian Aristoff, Heinrich J. Schostarez, Robert A. Chrusciel, Thomas R. Belliotti, Bruce R. Evans, Frank C. Sciavolino, Manuel A. Navia
  • DIAMINOPTERIDINE DERIVATIVES
    Publication number: 20120283219
    Abstract: The present invention relates novel diaminopteridine derivatives, their compositions and method of treatment comprising the same for use as anti-infectives.
    Type: Application
    Filed: March 25, 2010
    Publication date: November 8, 2012
    Inventors: Philip D.G. Coish, Phil Wickens, Brian R. Dixon, David Osterman, Uday R. Khire, Manuel Navia, Judd Berman, Harpreet Kaur, Jeffrey Wilson, Dennis Underwood